Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro

被引：0
|
作者：
Selvi Kunnimalaiyaan
Victoriana K. Schwartz
Iris Alao Jackson
T. Clark Gamblin
Muthusamy Kunnimalaiyaan
机构：
[1] Division of Surgical Oncology,
[2] Department of Surgery,undefined
[3] Medical College of Wisconsin,undefined
[4] C4763,undefined
[5] Translational and Biomedical Research Center,undefined
来源：
BMC Cancer | / 18卷
关键词：
GSK-3 inhibitor; Neuroblastoma; GSK-3 alpha; GSK-3 beta; Apoptosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
    Kunnimalaiyaan, Selvi
    Schwartz, Victoriana K.
    Jackson, Iris Alao
    Gamblin, T. Clark
    Kunnimalaiyaan, Muthusamy
    BMC CANCER, 2018, 18
  • [2] A phase I dose-escalation, pharmacokinetic (PK), and pharmacodynamic (PD) evaluation of intravenous LY2090314 a GSK3 inhibitor administered in combination with pemetrexed and carboplatin.
    Brail, L. H.
    Gray, J. E.
    Burris, H.
    Simon, G. R.
    Cooksey, J.
    Jones, S. F.
    Farrington, D.
    Lam, T.
    Jackson, K.
    Chow, K.
    Brandt, J. T.
    Infante, J. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia
    Rizzieri, David A.
    Cooley, Sarah
    Odenike, Olatoyosi
    Moonan, Lisette
    Chow, Kay Hoong
    Jackson, Kimberley
    Wang, Xuejing
    Brail, Leslie
    Borthakur, Gautam
    LEUKEMIA & LYMPHOMA, 2016, 57 (08) : 1800 - 1806
  • [4] GSK-3\#946; inhibitor SB415286 as chemotherapy for neuroblastoma
    Dickey, Amy
    Thotala, Dinesh
    Hallahan, Dennis
    Yazlovitskaya, Eugenia
    CANCER RESEARCH, 2009, 69
  • [5] Activating the Wnt/β-Catenin Pathway for the Treatment of Melanoma - Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3
    Atkinson, Jennifer M.
    Rank, Kenneth B.
    Zeng, Yi
    Capen, Andrew
    Yadav, Vipin
    Manro, Jason R.
    Engler, Thomas A.
    Chedid, Marcio
    PLOS ONE, 2015, 10 (04):
  • [6] Targeting GSK-3: a new approach for the treatment of neuroblastoma
    Dubrovskyi, Oleksii
    Ugolkov, Andrey
    Gaisina, Irina
    Bondarenko, Gennadiy
    Strizzi, Luigi
    Margaryan, Naira
    O'Halloran, Thomas
    Kozikowski, Alan
    Hendrix, Mary
    Mazar, Andrew
    CANCER RESEARCH, 2015, 75
  • [7] Antitumor effect of a novel GSK-3β inhibitor on renal cancer cells
    Anraku, Tsutomu
    Kuroki, Hiroo
    Vladimir, Bilim
    Andrey, Ugolkov
    Tasaki, Masayuki
    Takizawa, Itsuhiro
    Tomita, Yosihiko
    CANCER SCIENCE, 2018, 109 : 1141 - 1141
  • [8] Antitumor effect of a novel GSK-3 inhibitor on urothelial cancer cells
    Kuroki, Hiroo
    Anraku, Tsutomu
    Bilim, Vladimir
    Ugolkov, Andrey
    Tasaki, Masayuki
    Takizawa, Itsuhiro
    Tomita, Yoshihiko
    CANCER SCIENCE, 2018, 109 : 303 - 303
  • [9] GSK-3β inhibitor stimulates osteoblast differentiation in vitro and bone formation in vivo.
    Chen, M.
    Sheu, T.
    Zhu, M.
    O'Keefe, R. J.
    Chen, D.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S98 - S98
  • [10] Novel GSK-3 kinase inhibitor Pym-5 induces GSK-3β rather than GSK-3α-dependent melanogenesis in murine melanoma cells
    Jia, Qi
    Tao, Li
    Zhou, Yinyin
    Song, Li
    Wei, Zhonghong
    Lu, Tao
    Woodgett, James R.
    Lu, Yin
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2022, 106 (03) : 170 - 180
12345